Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weekly shot aims to melt away pounds in obesity fight

NCT ID NCT07822061

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers are testing a new once-weekly injection called NNC0487-0111 in about 400 Japanese adults with overweight or obesity. Half the participants receive the drug and half receive a placebo, assigned by chance. The main goal is to measure how much body weight changes over the study. The trial also tracks waist circumference and safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental once-weekly weight-loss injection called NNC0487-0111
What this could lead to
If it works, this could give Japanese adults with overweight or obesity another weekly injection option for weight loss.
What could go wrong
The trial may show the drug does not beat placebo, or side effects may outweigh the benefits. Results in Japanese participants may not apply to other groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female (sex at birth). * Age 18 years or above at the time of signing the informed consent. * For participants with T2D at screening (max 25%), the following inclusion criteria apply * Diagnosed with T2D ≥ 180 days before screening. * Haemoglobin A1c (HbA1c) 7.0 -10.0% (53-86 millimole per mole (mmol/mol) (both inclusive) as measured by the central laboratory at screening. * Treatment with lifestyle intervention, and/or with 0-3 marketed oral antidiabetic drugs (OADs) (Metformin, glinide, thiazolidinedione, sodium-glucose cotransporter-2 inhibitors, α-glucosidase inhibitors, imeglimin, or sulfonylureas (SU) as a single agent or in combination) according to local label. Treatment with OADs should be stable (same drug(s), dose and dosing frequency) before screening. * For participants with knee OA at screening (approximately 50 participants), the following inclusion criteria apply * Clinical diagnosis of knee OA (American College of Rheumatology criteria) with radio-graphic changes (Kellgren-Lawrence grades 2 to 3 as per central reading) in the target knee. Target knee joint is defined as most symptomatic knee at screening. If pain in knees is equal, the target knee joint will be the dominant leg. * Symptomatic knee OA with first appearance of pain in the target knee \> 90 days prior to screening and pain in the target knee for \> 15 days over the prior 30 days. * Willingness to complete a 72-hour washout period of analgesics before all visits in-volving WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) questionnaire (acetaminophen 4 gram/day is allowed as rescue medication up until 24 hours before those visits). Exclusion Criteria: \- Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening. For participants without T2D at screening (including participants with and without knee OA), the following exclusion criteria apply in addition to criterion 1 (above): * HbA1c ≥ 6.5% (48 mmol/mol) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus. * For participants with T2D at screening, the following exclusion criteria apply in addition to criterion 1 (above): * Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question 8. * Recurrent severe hypoglycaemic episodes within the last year as judged by the investigator. * Renal impairment with estimated Glomerular Filtration Rate (eGFR) \< 30 millilitre per minute per 1.73 m\^2, (2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (by creatinine)), at screening. * Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or are expected to require treatment within 180 days after screening. * Diabetic retinopathy or maculopathy must be verified by an eye examination per-formed within 90 days before screening or in the period between screening and randomisation. * Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. For participants with knee OA, the following exclusion criteria apply in addition to cri-teria 1-3 (above): * Any joint prosthesis or joint replacement in the target knee. * Arthroscopy or injections into the target knee within the last 90 days prior to screening. * Any other joint disease in the target knee including gout and pseudogout.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Knee osteoarthritis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder osteoarthritis, knee Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    26 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Akaicho Clinic_Internal medicine

    RECRUITING

    Chiba-shi, Chiba, 260-0804, Japan

  • Clinical Research Hospital Tokyo_Internal medicine

    RECRUITING

    Tokyo, 160-0004, Japan

  • Hayashi Diabetes Clinic_Internal Medicine and Diabetes Medicine

    RECRUITING

    Chigasaki-shi, Kanagawa, Japan, 253-0044, Japan

  • Iwamoto Internal Medicine Clinic_Diabetes Internal Medicine

    RECRUITING

    Kagawa, 765-0071, Japan

  • JCHO Kyushu Hospital_Department of Endocrinology and Metabolism

    NOT_YET_RECRUITING

    Kitakyushu-shi, Fukuoka, 806-8501, Japan

  • Kuroda Orthopedic Clinic_Orthopedic Surgery and Internal Medicine

    RECRUITING

    Fukuoka-shi, Fukuoka, 814-0165, Japan

  • Matsuba Clinic_Internal Medicine

    NOT_YET_RECRUITING

    Kawasaki-shi, Kanagawa, Japan, 212 0024, Japan

  • Morimoto Clinic_Pain Clinic

    NOT_YET_RECRUITING

    Osaka-shi, Osaka, 530-0041, Japan

  • Motomachi Takatsuka Naika Clinic_Internal Medicine

    NOT_YET_RECRUITING

    Kanagawa, 231-0023, Japan

  • Naka Kinen Clinic_Internal medicine

    RECRUITING

    Ibaraki, 311-0113, Japan

  • National Hospital Organization Kyoto Medical Center_Diabetic Center

    NOT_YET_RECRUITING

    Kyoto-shi, Kyoto, 612-8555, Japan

  • OCROM Clinic_Internal medicine

    NOT_YET_RECRUITING

    Suita-shi, Osaka, 565-0853, Japan

  • Seino Internal Medicine Clinic_Internal medicine

    RECRUITING

    Koriyama-shi, Fukushima, 963-8851, Japan

  • Shinsapporo Seiryou Hospital_General Clinical Department

    RECRUITING

    Sapporo, Hokkaido, 004-0004, Japan

  • Suidoubashi Medical Clinic_Internal Medicine

    RECRUITING

    Chiyoda-ku, Tokyo, 101-0065, Japan

  • TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology

    RECRUITING

    Aichi, 468-0009, Japan

  • Takai Internal Medicine Clinic_Internal Medicine

    RECRUITING

    Kamakura-shi, Kanagawa, 247 0056, Japan

  • The University of Osaka Hospital_Metabolic Medicine

    RECRUITING

    Osaka, 565-0871, Japan

  • The University of Tokyo Hospital, Diabetes and Metabolic

    NOT_YET_RECRUITING

    Bunkyo-ku, Tokyo, 113-8655, Japan

  • ToCROM Clinic_Internal Medicine

    RECRUITING

    Tokyo, 160-0008, Japan

  • Tokuyama clinic_Diabetic internal medicine

    NOT_YET_RECRUITING

    Chiba, 261-0004, Japan

  • Tokyo Asbo Clinic_Internal Medicine

    RECRUITING

    Chuo-ku, Tokyo, 104-0031, Japan

  • Tokyo-Eki Center-building Clinic_Internal Medicine

    NOT_YET_RECRUITING

    Tokyo, 103-0027, Japan

  • Tsuruma Kaneshiro Diabetes Clinic_Internal medicine

    NOT_YET_RECRUITING

    Yamato-shi, Kanagawa, 242-0004, Japan

  • Yao Tokushukai General Hospital_Internal medicine

    RECRUITING

    Yao City, Osaka, 581-0011, Japan

  • Yokohama Minoru Clinic_Internal medicine

    NOT_YET_RECRUITING

    Kanagawa, 232-0064, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.